Effects of variable domain orientation on anti‐HER2 single‐chain variable fragment antibody expressed in the Escherichia coli cytoplasm

Abstract

Single‐chain variable fragment (scFv) antibodies have great potential for a range of applications including as diagnostic and therapeutic agents. However, production of scFvs is challenging because proper folding and activity depend on the formation of two intrachain disulfide bonds that do not readily form in the cytoplasm of living cells. Functional expression in bacteria therefore involves targeting to the more oxidizing periplasm, but yields in this compartment can be limiting due to secretion bottlenecks and the relatively small volume compared to the cytoplasm. In the present study, we evaluated an anti‐HER2 scFv, which is specific for human epidermal growth receptor 2 (HER2) overexpressed in breast cancer, for functional expression in the cytoplasm of Escherichia coli strains BL21(DE3) and SHuffle T7 Express, the latter of which is genetically engineered for cytoplasmic disulfide bond formation. Specifically, we observed much greater solubility and binding activity with SHuffle T7 Express cells, which likely resulted from the more oxidative cytoplasm in this strain background. We also found that SHuffle T7 Express cells were capable of supporting high‐level soluble production of anti‐HER2 scFvs with intact disulfide bonds independent of variable domain orientation, providing further evidence that SHuffle T7 Express is a promising host for laboratory and preparative expression of functional scFv antibodies.

Document Details

Document Type
Pub Defense Publication
Publication Date
Nov 20, 2020
Source ID
10.1002/btpr.3102

Entities

People

  • Eda Çelik
  • Emily C. Cox
  • Matthew P. DeLisa
  • İlkay Koçer

Organizations

  • Cornell University
  • Defense Threat Reduction Agency
  • Hacettepe University
  • National Institutes of Health
  • National Science Foundation
  • TÜBİTAK

Tags

Fields of Study

  • Biology

Readers

  • Electrochemical Engineering/ Fuel Cell Technologies
  • Immunology
  • Microbial Pathology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech